Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 2009. The document serves as a notification of a transaction involving a director, specifically a change in interest in the company's ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is strictly a regulatory disclosure regarding a director's share transaction and does not contain financial performance data.
Material Changes
The material change disclosed is an increase in the shareholding of Mr. A P Witty. This arose from the purchase of one ordinary share on June 4, 2009, following the reinvestment of a cash reserve on shares held within an Individual Savings Account (ISA). The transaction price was £10.36 per ordinary share.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The transaction was notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Director Involved: Mr. A P Witty.
- Transaction Date: June 4, 2009.
- Transaction Type: Purchase of one ordinary share via ISA cash reserve reinvestment.
- Share Price: £10.36.
- Notification Date: The company and the director were advised on June 10, 2009.